Real-world cohort data reveal systemic nicotinamide use is associated with a 66% reduction in POAG conversion risk in patients with ocular hypertension.
Randomized clinical trials demonstrate nicotinamide improves inner retinal function and visual field measures in established glaucoma.
Niacinamide supplementation enhances quality of life metrics and modestly lowers intraocular pressure, supporting multifaceted benefits.
Ongoing trials combining nicotinamide with pyruvate aim to elucidate metabolic neuroprotection mechanisms and optimize glaucoma management strategies.
